


INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES



INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES



Advisory Editorial Board Members

Dr. Muhammad Akhyar Farrukh, Pakistan
 Dr. Aziz-Ur-Rehman, Pakistan
 Dr. Ahmad Khan, Pakistan
 Dr. Furhan Iqbal, Pakistan
 Dr. Ebtessam Ahmed Mohammed Essa, Egypt
 Dr. Fazli Khuda, Pakistan
 Dr. Akhilesh Kumar, India
 Dr. Akbar Esmaili, Pakistan
 Dr. Andleeb Shahzadi, Pakistan
 Dr. Shahzadi, Malaysia
 Dr. Rafeeq Alam Khan, Saudi Arabia
 Dr. Syed Muhammad Farid Hasan, Pakistan
 Dr. Khaled Nabih Zaki Rashed, Egypt
 Dr. Sheikh Abdul Khaliq, Pakistan
 Ms. Isabel Cristina Pinto Valença, Portugal
 Dr. Abdel Raheem Mohammed Ahmed Donia, Egypt
 Dr. C.Chellaram, India
 Mr. Koshana Kollo Kawuda, Ethiopia
 Dr. Ahmed Mohammed Kabel, Egypt
 Dr. Dr. Niaz Ali, Pakistan
 Dr. Huma Ikram, Pakistan
 Dr. M. Saeed Arayne, Pakistan
 Dr. Wanzala Wycliffe, Kenya
 Dr. Salah Akkal, Algeria
 Dr. Abdul Aziz, Pakistan
 Dr. Amer A. Taqa, Iraq
 Dr. Anup Naha, India
 Dr. Deepak Kumar, India
 Dr. Devang J. Pandya, India
 Dr. Eman Abdel-Samlaa All Hussein Alam, Pakistan
 Dr. Evren Algin Yapar, Turkey

Editorial Board

Editor-in-Chief

Prof. M. S. Bhatia, India
 Bharati Vidyapeeth College of Pharmacy, Kolhapur, India
 Email: manish.bhatia@bharativedyapeeth.edu
 Email: editor@ijppsjournal.com

Associate Editor

Dr. Avijeet Jain, India
 Shri Sathya Sai Institute of Pharmaceutical Sciences, Bhopal, India
 Email: avijeet_9826275340@rediffmail.com

Dr. Subhash C Mandal, India
 Pharmacognosy & Phytotherapy Research Laboratory, Department of Pharmaceutical
 Technology, Jadavpur University, Kolkata, India
 Email: subhashmandal@yahoo.com

Dr. Lokesh Deb, India
 Medicinal Plants and Horticultural Resources Division, Institute of Bioresources and
 Sustainable Development (IBSD), (Department of Biotechnology, Government of India),
 Takyelpat Institutional Area, Imphal, Manipur, India.

Dr. Wong Tin Wui, Malaysia
 Non-Destructive Biomedical and Pharmaceutical Research Center, University of
 Technology MARA, Malasiya
 Email: wongtinwui@yahoo.com

Assistant Editor

Dr. Idress Hamad Attittala, Libya
 Omar El-Mukhtar University, Faculty of Science, Botany Department, El-Beida, Libya
 Email: idressattittala2004@yahoo.com

Dr. Alok Nahata, Malaysia
 Alor Star, Malaysia
 Email: aloknahata@gmail.com

Executive Editor

Mr. Niranjan Pathak, India
 Dept. of Pharmaceutical Sciences, Dr H S Gour Central University, Saugor, India
 Email: niranjanpathaklib@gmail.com

Editorial Board Members

Prof. Mohamed Eddouks, Morocco	Dr. Saifullah Khan, Malasiya
Prof. Ahmed Osman, Malaysia	Dr. Shazia Jamshed, Malasiya
Prof. Mueen Ahmed K. K., India	Dr. T. Jeyanthi, India
Prof. B. M. Patil, India	Dr. Mayuree Tangkiatkmjai, Thailand
Prof. Syed Azhar Syed Sulaiman, Malaysia	Dr. Hireen Chandrakant Mandalia, India
Prof. Joao B. Calixto, Brazil	Dr. Noha Mohamed Zaki Rayad, Egypt

Dr. Ajit Joshi, India
 Dr. M. Mathrusri, India
 Dr. Arun Kumar Subramanian, India
 Dr. Behzad Foroutan, Iran
 Dr. Tarek Saied Fathalla Belal, Egypt
 Dr. Bhaskara Rao Rayini, India
 Dr. C. S. Chidan Kumar, India
 Dr. Shyamal Chandra Das, New Zealand
 Dr. Md. Golam Azam, Bangladesh
 Dr. Dr. B.L. Dhananjaya, India
 Dr. Samah Djeddi, India
 Dr. Arugadoss Devakumar (Doss), USA
 Dr. Md. Moklesur Rahman Sarker, Japan
 Dr. Sharangouda J. Patil, India
 Dr. Duc P. Do, Chicago
 Dr. S.Gowtham Kumar, India
 Dr. Niyati S. Acharya, India
 Dr. P. THILLAI ARASU, India
 Dr. Rashad Mohammed Musleh, Alnamer, Yemen
 Dr. Shamkuwar Prashant Babarao, India
 Dr. Shankar Swaminathan, USA
 Dr. Sooraj S. Nath, India
 Dr. Wesley Lyevertton Correia Ribeiro, Brazil
 Dr. Abdel-Tawab Halim Mossa Abd El-Aziz, Egypt
 Dr. Naveed Muhammad, Pakistan
 Dr. Yasser Shahzad
 Dr. Ammar Al-Temimi, Iraq
 Dr. Aysu Yurdasiper, Turkey
 Dr. Bing Hu, China
 Dr. Ching Siew Mool, Malasiya
 Dr. Erum Shireen, Pakistan
 Dr. M.M.Gupta, West Indies
 Dr. Najma Sultana, Karachi
 Dr. Norhaniza Aminudin, Malasiya
 Dr. Rajesh Mukthavaram, California
 Mr. Jie Feng, China
 Dr. Mohmad Farooq Shaikh, Malasiya
 Dr. Hao Wu, USA
 Dr. Laila A Abou Zeid, Egypt
 Dr. Adriano Mollica, Italy
 Dr. Arvind Gulbake
 Mr. Praveen Kumar Gaur, India

Dr. Shalini Sivadasan, Malaysia
 Mr. N. Tamil Selvan, India
 Mr. B.Anbarasi, India
 Mr. M. Arun Sundar, India
 Mr. Vibhor Kumar Jain, India
 Mr. Mohd Yusuf, India
 Mr. James John, India
 Mr. Kalzar Hossain, India
 Mr. K. Mallikarjuna Rao, India
 Mr. Ramdayal Gupta, India
 Mr. Gondaliya Rajesh Jagdishbhai, India
 Mr. Ramalakshmi S, India
 Mr. M. Ramgopal, India
 Mr. Sudhanva Tipare, India
 Mr. Tariq Mahmood, Pakistan
 Miss Vijayalakshmi, India
 Mr. Muhammad Akram, India
 Dr. Shahzad Aslam, Pakistan
 Mr. Mohammed Rageeb Mohammed Usman, India
 Mr. Akhilesh Dubey, India
 Mr. E V N Raju, India
 Mr. Jitendra O. Bhangale, India
 Mr. Mayank Kushreshtha, India
 Mr. Md. Morshedul Alam, Japan
 Mr. Mohd. Abdul Hadi, India
 Mr. Pranav P. Parekh, India
 Mr. Sachin Bhaskar Narkhede, India
 Mr. Sainul Abideen. P, India
 Mr. Sundram, Malasiya
 Mr. Ambuj Kumar, Florida
 Mr. Ramesh B. Nidavani, India
 Dr. Nagib Ali Elmarzugi, Malasiya
 Dr. Manzoor Ahmad Rather, India
 Dr. Hafiz Muhammad Asif, Pakistan
 Dr. TianxLang (Kevin) Han, USA
 Dr. Wanyi Tai, USA
 Dr. JING TONG, USA
 Dr. Fongwu Shen, USA
 Dr. Syed Siraj Ahmed Quadri, Vergenia
 Dr. Kaushalkumar Dave, USA

Editorial Office

International Journal of Pharmacy and Pharmaceutical Sciences
 C/o Avijeet Jain
 6/1, Sanjeevani Medical Stores, Shastri Chowk
 Sadar Bazar, Sagar
 Madhya Pradesh, India
 E mail- editor@ijppsjournal.com

Open Access Policy || Contact Us || Publication Ethics

All Rights Reserved @ Innovare Academic Sciences Pvt. Ltd || Powdered By: CyberDairy | Anchal

- Dr. Goverdhan Puchchakayala, India
 Dr. Ibrahim Salih Abbas Al-Jubouri, Iraq
 Dr. Jagdish Labhubhai Kakadiya, India
 Dr. Jayanta Kumar Patra, South Korea
 Dr. Maha Ali Eissa Ahmed, Egypt
 Dr. Manish Jaimini, India
 Dr. Manoj Kumar Mishra, India
 Dr. Milind Sadashiv Alai, Taiwan
 Prof. Dr. Mohamed Salama, Egypt
 Dr. Sivakumar P, India
 Dr. Xiangming (Kain) Wu, Corvallis
 Mr. Ramesh B. Nidavani, India
 Dr. Amit Kumar Tyagi, USA
 Dr. Sahdeo Prasad, USA
- Prof. Hakan Arslan, Turkey
 Prof. J. Peter Krause, Germany
 Prof. Sujimon Tanvichien, Nakornayok
 Prof. Ing. habil. Dr. h. c. Lothar Mörl, Germany
 Dr. V. Ravichandran, Malaysia
 Dr. Sushil K Kashaw, India
 Dr. Kumaresh Soppimath, USA
 Dr. Vishal Vijay Pandey, India
 Dr. Rajesh Kumar, India
 Dr. Rajesh Kumar Neema, India
 Dr. Vijay Dhondiram Wagh, India
 Dr. Ritu Mehra Gilhotra, India
 Dr. Rakesh Patel, India
 Dr. Mayank Thakur, Germany
 Dr. (Mrs.) Deepshikha Pande Katare, India
 Dr. (Mrs.) Supriya Shrihari Shidhaye, India
 Dr. Shreesh Kumar Ojha, USA
 Dr. Chitra Telang, USA
 Dr. Ajay Kumar Meena, India
 Dr. L. D Patel, India
 Dr. Parveen Bansalani, India
 Dr. Ashish C. Suthar, India
 Dr. Jayvandan K Patel, India
 Dr. Sabyasachi Maiti, India
 Dr. David Banji, India
 Dr. Ekta Manghani, India
 Dr. Guang Yan, China
 Dr. Chandan M Thomas, Florida
 Dr. Bhaskar Mazumdar, India
 Dr. Manish A. Rachchh, India
 Dr. Asif Husain, India
 Dr. Awani K Rai, India
 Dr. Jackson Clement, Nigeria
 Dr. Sanjay Kalra, India
 Dr. A Lakshmana Rao, India
 Dr. Hari R Desu, USA
 Dr. S Gunasakaran, India
 Dr. Javed Intekhab, India
 Dr. Ahmed Hussain, India
 Dr. Manish P Patel, India
 Dr. Narendra Babu Shivanagere, India
 Dr. Omar Abdulraheem Sarheed, Scotland
 Dr. Praveen K Vishwanath Ingle, India
 Dr. Pranay Jain, India
 Dr. Rajiv K Chawla, India
 Dr. Mehdi Shafiee Ardestani, Iran
 Dr. Sunil Agnihotri, USA
 Dr. Anil Kumar Uttamchand Tatiya, India
 Dr. Vijayababu MR, India
 Dr. Xiaoli Gao, USA
 Dr. Ali Aboel Dahab, UK
 Dr. Adrian Chrastina, Europe
 Dr. Amal Amin Mohamed, Egypt
 Dr. Barkat Ali Khan, Pakistan
 Dr. Rabab Kamel Mahmoud, Egypt
 Dr. Longfei Huo, USA
 Dr. Mok T. Chong, USA
 Dr. Chakraborty, India
 Dr. Shailendra Shivaji Gurav, India
 Dr. S. K. Starling, India
 Dr. Syed Adnan Ali Shah, Malaysia
 Dr. Muhammad Yousuf Khan, UK
 Dr. Alaa Eldin Ahmed Hamza, Egypt
 Dr. Beduin Mahant, India
 Dr. Sat Pal Singh Bisht, India
 Dr. Pr. Mohamed Bnouham, Morocco
 Dr. Shahu Ingole, India
 Dr. Gina Samy El-Feky, Egypt
 Dr. Abdalla Ahmed Elbashir Ahmed, Sudan
 Dr. Li, Ming, China
- Dr. Nishant Gupta, India
 Dr. Prakash. MMS. Kinthada, India
 Dr. Yesudass Dominic Ravichandran, India
 Dr. (Mrs) Seema Akbar, India
 Dr. G. Vidyasagar, India
 Dr. Wenshou Wang, Minneapolis
 Dr. Md. Zaki Ahmad, India
 Dr. Ahmed Gorbani, India
- Dr. Omid Panahi, Iran
 Dr. Peng Zou
 Dr. Madhusudan. Purohit, India
 Dr. Rajeswara Reddy Saddala, India
 Dr. Rakesh Sagar, India
 Dr. Ram Kumar Pundir, India
 Dr. Rituraj Purohit, India
 Dr. Rohini K, Malaysia
 Dr. Santhosh M. Mathews, India
 Dr. Shiekh Tanveer Ahmad, India
 Dr. Sushama Talegaonkar, India
 Dr. Izhar Ahmed Syed, India
 Dr. T. Murugan, India
 Dr. Kedam Thyaga Raju, India
 Dr. P. Venkatesan, India
 Dr. Vivek S. Dave, India
 Dr. Chakka Gopinath, India
 Dr. Ismail Murat Palabiyik, Turkey
 Dr. Hasniza Binti Zaman Huri, Malaysia
 Dr. Lingdong Quan, USA
 Dr. Nadeem A. Kizilbash, Arabia
 Dr. Chirag m. Modi, India
 Dr. Chandeshwari Chilampalli, USA
 Dr. Ram Pramod Tiwari, India
 Dr. Gali Vidya Sagar, India
 Dr. Ismail Ahmed Ismail Abdel, Egypt
 Dr. Rozi Muhammad, Pakistan
 Dr. Debajit Kalita, India
 Dr. Harsha Kharkwal, India
 Dr. V. Vinod Prabhu, India
 Dr. Abdul Wahab, Pakistan
 Mr. Nagendra Singh Chauhan, India
 Mr. Ravi Kumar, India
 Mr. Eman Abdel-Samlaa Ali Hussein Alam, Egypt
 Mr. Abhinav Agarwal, India
 Mr. Neeraj Gilhotra, India
 Mr. Abhay R. Shirode, India
 Mr. Kalpesh Gaur, India
 Mr. Deepak Jain, India
 Mr. Vikas Sharma, India
 Mr. Rakesh K Tekade, India
 Mr. D. Nagasamy Venkatesh, India
 Mr. Seyed Mohammad Nabavi, Iran
 Mr. Yogesh Murti, India
 Mr. Tarak Parekh, India
 Mr. Gaurav Tiwari, India
 Mr. G V Suresh Kumar, India
 Mr. R. Manivannan, India
 Mr. Amit J Kasabe, India
 Ms. Bindu Jain, India
 Mr. Bhabani Shankar Nayak, India
 Mr. Dinesh L Dhamecha, India
 Mr. K Maillamani, India
 Ms. Ruchi Tiwari, India
 Mr. M R Shivalingam, India
 Mr. Vibhor Kumar Jain, India
 Mr. Chetan Sharma, India
 Mr. E.K. Elumalai, India
 Mr. Javed Shaikh, India
 Mr. Kapil Kalra, India
 Mr. Ravindra Reddy Yaramala, India
 Mr. Gajanan A. Vaishnav, India
 Mr. Swatantra K. S. Kushwaha, India
 Mr. Thirumalai. T, India
 Mr. Dibyajyoti Saha, India
 Mr. Rajendra Vivek Bhaskar, India
 Mr. Yasser Shahzad, UK
 Mr. Harshal Ashok Pawar, India
 Mr. Gajanan S. Sanap, India
 Mr. Gaurav Kumar, India
 Mr. Harekrishna Roy, India
 Ms. Jhansee Mishra, India
 Mr. Kallash Bansal, India
 Mr. L. Karthik, India
 Ms. Lakshmi T, India
 Mr. Manish Kumar, India
 Dr. Manoj M. Nitalikar, India
 Mr. Syed Sajjad Hussien, India
 Mr. Sarath Babu Kurra, India

MOLECULAR DOCKING STUDIES OF PHENYLAMINOPYRIMIDINE AND PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES AS JANUS KINASE 2 (JAK2) INHIBITORS	225-230
RAJASEKHAR CHEKKARA, NARESH KANDAKATLA, VENKATA REDDY GORLA,, SOBHA RANI TENKAYALA,, SUSITHRA ETHIRAJ	
NANOEMULSION LOADED WITH MARIGOLD FLOWER EXTRACT (<i>TAGETES ERECTA</i> LINN) IN GEL PREPARATION AS ANTI-WRINKLES COSMECEUTICAL	231-236
PIMPORN LEELAPORNPISED, KANOKWAN KIATTISIN, PENSAK JANTRAWUT AND AMPAI PHRUTIVORAPONGKUL.	
FORMULATION AND EVALUATION OF GASTRORETENTIVE BEADS OF RANITIDINE HYDROCHLORIDE	237-242
RAJKUMAR PATEL, RITESH S. BATHE, DEEPAK KHOBRAGADE, SACHIN JADHAV	
EVALUATION OF ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY OF METHANOLIC EXTRACT OF <i>CURCUMA CAESIA</i> ROXB. RHIZOMES IN LABORATORY ANIMALS	243-247
SAMPADA BHOSALE SAWANT, GOPAL BIHANI, SMEETA MOHOD, SUBHASH BODHANKAR	
FORMULATION AND <i>IN VITRO</i> STUDY OF KETOPROFEN PSEUDOLATEX GEL FOR TRANSDERMAL DRUG DELIVERY SYSTEMS	248-253
JIRAPORNCHAI SUKSAEEREE, CHAOWALIT MONTON, APIRAK SAKUNPAK, AND TOSSATON CHARONNATANA	
PHYTOCHEMICAL ANALYSIS OF THE LEAVES OF <i>CLERODENDRUM VISCOSSUM</i> VENT.	254-258
PRIYANKAR DEY, SOMIT DUTTA, TAPAS KUMAR CHAUDHURI	
FORMULATION AND <i>IN-VITRO</i> EVALUATION OF MODIFIED RELEASE TABLETS OF GLICLAZIDE (ANTIDIABETIC DRUG)	259-261
SANJAY K. SHARMA, SHAILENDER MOHAN, MANISH JAIMINI	
ISOLATION, CHARACTERIZATION AND <i>INSILICO</i> PHARMACOLOGICAL SCREENING OF MEDICINALLY IMPORTANT BIO-ACTIVE PHYTOCONSTITUENTS FROM THE LEAVES OF <i>IPOMOEA AQUATICA</i> FORSK.	262-267
D. SIVARAMAN , P. PANNEERSELVAM AND P. MURALIDHARAN	
EVALUATION OF ANTIOXIDANT CAPACITIES, FLAVONOID, PHENOLIC, CAROTENOID CONTENT FROM VARIOUS EXTRACTS OF FOUR KINDS BRASSICA HERBS	268-272
IRDA FIDRIANNY, PUSPA UTARI, KOMAR RUSLAN W	
ANTIDIABETIC ACTIVITY AND ANTI-OXIDANT ACTIVITY OF NIDDWIN, A POLYHERBAL FORMULATION IN ALLOXAN INDUCED DIABETIC RATS	273-277
T. SRUTHI, D. SATYAVATI, K. UPENDAR, C. PRADEEP KUMAR	
NEW SPECTROPHOTOMETRIC ESTIMATION OF PRULIFLOXACIN USING 2,4- DINITROPHENYL HYDRAZINE REAGENT	278-280
SWEETY S KANOLKAR, TEJA V WALKER	
COST-COST ANALYSIS OF ANTI-DIABETIC THERAPY IN A TERTIARY HEALTHCARE INSTITUTION, NORTH-EASTERN NIGERIA	281-286
GIWA ABDULGANIYU, TAYO FOLA	
GENOMIC AND PROTEOMIC SIGNATURES OF RADIATION AND THERMOPHILIC ADAPTATION IN THE <i>DEINOCOCCUS-THERMUS</i> GENOMES	287-300
RACHANA BANERJEE, ALAN ROY, SUBHASIS MUKHOPADHYAY	
ANTI - INFLAMMATORY POTENTIAL OF AQUEOUS EXTRACT OF <i>SESBANIA SESBAN</i> (L) MERR	301-304
KATHIRAVAN SUBRAMANIAN , SHWETHA V KALAVA	
EFFICACY OF INTRA-PERITONEAL ADMINISTRATION OF METFORMIN AND 5-FLUORURACIL IN PREVENTION OF INDUCED-COLORECTAL ABERRANT CRYPT FOCI IN MICE	305-308
ABDULKAREEM H.ABD, ALAA GHANI HUSSEIN, AHMED SALIM MAHMOOD	
DEVELOPMENT AND VALIDATION OF KNOWLEDGE, ATTITUDE, PRACTICE QUESTIONNAIRE FOR ASTHMA AND ASSESSMENT OF IMPACT OF PATIENT EDUCATION ON ASTHMA PATIENTS	309-311
RAJANANDHMG, NAGESWARIAD , ILANGOK	
<i>IN VIVO</i> COMPARATIVE BIOAVAILABILITY STUDY OF TWO VALPROIC ACID SYRUP FORMULATIONS DISPENSED IN GAZA STRIP	312-314
ISSAM ABUSHAMMALA, MAJ RAMADAN, IBTHAL ELASTAL	
SYNTHESIS AND ANTITUMOR ACTIVITY EVALUATION OF <i>N,N'</i> -DIBENZOYL- <i>N,N'</i> -DIETHYLUREA AGAINST HUMAN BREAST CANCER CELL LINE (MCF-7)	315-318
NUZUL WAHYUNING DIYAH, JUNI EKOWATI, SISWANDONO	
A COMPARATIVE EVALUATION OF ANTICANCER ACTIVITIES OF FLAVONOIDS ISOLATED FROM <i>MIMOSA PUDICA</i> , <i>ALOE VERA</i> AND <i>PHYLLANTHUS NIRURI</i> AGAINST HUMAN BREAST CARCINOMA CELL LINE (MCF-7) USING MTT ASSAY	319-322
JOBY JOSE, SUDHEESH SUDHAKARAN, SUMESH KUMAR T.M, SONY JAYARAMAN, E. JAYADEVI VARIYAR	
INCIDENCE OF ACUTE AND CHRONIC FORMS OF LEUKEMIA IN HARYANA	323-325
RADHA RATHEE, MINAKSHI VASHIST, ASHOK KUMAR, SUNITA SINGH	
EVALUATION OF ANALGESIC ACTIVITY OF BENZAPRIL IN ALBINO MICE	326-328
SIDDAMMA.AMOGHIMATH, SURESHA R N, VAIBHAVI P S	
DOCKING BASED PHARMACOPHORE MODEL FOR <i>MYCOBACTERIUM TUBERCULOSIS</i> PEPTIDE DEFORMYLASE INHIBITORS AND ITS APPLICATION IN DRUG DESIGNING	329-331
PARVEEN PUNIA, SANDEEP SINGH, TILAK RAJ, K. RAGUVARAN, MEENU CHOPRA AND VIKAS DAHIYA	
FORMULATION AND EVALUATION OF MUCOADHESIVE BUCCAL FILMS OF ATORVASTATIN USING NATURAL PROTEIN	332-337
DR. ANNA BALAJI, B. KRISHNAVENI, VISHNUVARDHAN GOUD	
ANTI HYPERLIPIDEMIC EFFECT OF AQUEOUS EXTRACT OF <i>AEGLE MARMELOS</i> AND <i>CAMELLIA SINENSIS</i> IN OIL FED HYPERLIPIDEMIC RATS	338-341
PRIYANGA SURIYAMOORTHY, MARGRET ROSALAND FATHIMA MARY, HEMMALAKSHMI SUBRAMANIAN, DEVAKI KANAGASAPABATHY	
USE OF HERBAL NANO SILVER FOR FABRICATION OF ANTIMICROBIAL COTTON FABRICS AND TESTING ITS EFFICACY AGAINST MICROBES	342-346
AYNUL RIFAYA, M. AND MEYYAPPAN, R.M.	
VALIDATED NORMAL PHASE HPTLC METHOD FOR SIMULTANEOUS QUANTIFICATION OF LEVOSULPRIDE AND ESOMEPRAZOLE IN CAPSULE DOSAGE FORM	347-350
PRAVIN D. PAWAR, SATISH Y. GABHE, SACHIN E. POTAWALE, KAKASAHEB R. MAHADIK	



International Journal of Pharmacy and Pharmaceutical Sciences

Country India -  SIR Ranking of India

Subject Area and Category Pharmacology, Toxicology and Pharmaceutics
Pharmaceutical Science
Pharmacology

Publisher International Journal of Pharmacy and Pharmaceutical Sciences

Publication type Journals

ISSN 09751491

Coverage 2009-2016 (cancelled)

Scope International Journal of Pharmacy and Pharmaceutical Sciences (Int J Pharm Pharm Sci) is peer-reviewed, monthly (Onward April 2014) open access Journal. IJPPS publishes original research work that contributes significantly to advance the scientific knowledge in pharmacy and pharmaceutical sciences including Pharmaceutical Technology, Pharmaceutics, Novel Drug Delivery, Biopharmaceutics, Pharmacokinetics Pharmacognosy and Natural Product Research Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmaceutical Analysis Pharmacology, Pharmacy Practice, Clinical and Hospital Pharmacy Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics, Pharmacoeconomics Research outcomes from medical sciences/case study and biotechnology of pharmaceutical interest are also considered. IJPPS publishes original research work either as an Original Article or as a Short Communication. Review articles on the current topic under mentioned scopes are also considered for publication. In addition, a hypothesis is also invited now for the publication onwards March 2016.



[Homepage](#)

[How to publish in this journal](#)

[Contact](#)










[Join the conversation about this journal](#)

37

H Index

Quartiles





International Journal of Pharmacy and... ← Show this widget in your own website

Pharmaceutical Science

Q2 best quartile

SJR 2018 0.23

powered by scimagojr.com

Just copy the code below and paste within your html code:

```
<a href="https://www.scima
```

M mohd.abdul.khader 3 weeks ago

hello, respective member's i wanted to submit my research article in this journal but it indicates some cancellation can u please guide me on what does this cancellation mean ?

reply

SYNTHESIS AND ANTITUMOR ACTIVITY EVALUATION OF *N,N'*-DIBENZOYL-*N,N'*-DIETHYLUREA AGAINST HUMAN BREAST CANCER CELL LINE (MCF-7)

NUZUL WAHYUNING DIYAH*, JUNI EKOWATI*, SISWANDONO*

*Faculty of Pharmacy Airlangga University Jl. Dharmawangsa Dalam Surabaya 60286, Indonesia. Email : nuzul_wd@yahoo.com

Received: 14 Jan 2014, Revised and Accepted: 27 Feb 2014

ABSTRACT

Objective: To find new antitumor agents a serie of ring-substituted *N,N'*-Dibenzoyl-*N,N'*-Diethylureas (3a-d) were designed and synthesized. The study was conducted to synthesize *N,N'*-Dibenzoyl-*N,N'*-Diethylureas and examine their antitumor activity against human breast carcinoma cell line (MCF-7).

Methods: The compounds were synthesized from reaction of *N,N'*-diethylurea with ring-substitued-benzoylureas. The molecular structures were confirmed by FTIR, ¹H-NMR, ¹³C-NMR and MS spectroscopy. Their antitumor activities were tested *in vitro* against human breast carcinoma cell line (MCF-7) using MTT assay. *In silico* molecular modeling was carried out through docking the compounds into binding site of ERK2 (PDB. 1TVO).

Results: The tested compounds exhibited antitumor activity higher than reference drug hydroxyurea. One of them (3c) displayed the highest activity among the tested compounds with IC₅₀ 0.56 μM, twenty-fold more active than hydroxyurea (IC₅₀= 11.58 μM). This compound more fitting to the enzyme's binding site than hydroxyurea could explain its better inhibitory activity.

Conclusion: Four ring-substituted *N,N'*-Dibenzoyl-*N,N'*-Diethylurea derivatives had been synthesized and one of them is highly potential as antitumor agents against human breast carcinoma cell line (MCF-7).

Keywords: *N, N'*-Dibenzoyl-*N,N'*-Diethylurea, Antitumor, MCF-7 cell line, Docking, ERK2.

INTRODUCTION

Cancer is one of the major causes of death in developing countries and also in the worldwide. In Indonesia, the cancer became the third largest contributor to death after heart disease. Since 2007 breast cancer reached first ranks for in-patients in hospitals, followed by cervical cancer [1]. It is still ongoing efforts to find new anticancer drugs because long used drugs have gradually become less effective and there is a tendency of resistance [2]. Cancer chemotherapy has entered a new era of molecularly targeted therapeutic agents, which targeting mutant oncogenic Growth Factor Receptor and non-receptor tyrosine kinases involved in mitogenic or proliferative signal transduction pathways in cancer cells [3]. The mitogen activated protein (MAP) kinase family regulates biological processes including cell growth, proliferation, differentiation, and programmed cell death. The extracellular signal-regulated kinase (ERK 1/2) is one of the three main members of MAP kinases which are important mediators of cell proliferation [4]. Constitutive activation of the ERK proteins plays an important role in the proliferation of some human cancers including breast, ovarian, colon, and prostat [5]. MAP kinases may be promising targets of new cancer chemotherapy.

Urea derivatives have been used as anticancer drugs, such as carmustine/BCNU (bis-chloroethylnitrosourea), ENU (*N*-ethyl-*N*-nitrosourea), and hydroxyurea. The presence of alkyl groups in could increase the hydrophobic character of the nitrosourea derivatives so that the compound can penetrate the blood-brain barrier [2]. Hydroxyurea could acted as antimetabolite that inhibit the ribonucleotide reductase and also targeted histone deacetylase and matrix metalloproteinase [6,7,8]. New urea derivatives have also been reported as a tyrosine kinase inhibitor and has become an important class of anticancer drugs [9]. Therefore it is still interesting to synthesis of urea derivatives as anticancer compounds. A serie of ring-substituted benzoylurea derivatives had synthesized and showed CNS depressant activity in mice [10]. Further reseach reported that those benzoylurea derivatives were more active than hydroxyurea according to Brine Shrimp Lethality Test so they were potential to develop as anticancer agent. Quantitative Structure Activity Relationship and *in silico* study of the benzoylureas using ribonucleotide reductase (3HNC) revealed that binding affinity of benzoylurea derivatives to the enzyme were better than hydroxyurea. Their cytotoxic activity was influenced by steric (MR) and hydrophobic (log P) factors and the presence of

aromatic ring in the structure of urea had increased its bioactivity [11]. In order to find more potent urea antitumor agents, we modified the urea structure by attached two ethyl groups and substituted aromatic ring on the two N atom generated some *N,N'*-dibenzoyl-*N,N'*-diethylurea derivatives. The antitumor activity of the new compounds were evaluated against human breast cancer cell line (MCF-7). The molecular interaction model for their cytotoxicities were performed by docking the molecules into the X-ray crystallographic structure of ERK2 in complex with an inhibitor [12] using Molegro Virtual Docker.

MATERIALS AND METHODS

Materials

The *N,N'*-Dibenzoyl-*N,N'*-Diethylureas (3a-d) were synthesized from the reaction of starting material *N,N'*-diethylurea (2) with several ring-substituted benzoyl chlorides (1) (Fig.1). The structure of synthesized compound were identified by IR, ¹H-NMR, ¹³C-NMR, and MS spectroscopy; whereas their purity were determined by melting point and TLC tests.




Fig. 1: Scheme of synthesis reaction of *N,N'*-dibenzoyl-*N,N'*-diethylurea

General Experimental

All reagents and solvents were purchased from standard commercial suppliers. Melting points were measured with an Electrothermal melting point apparatus without correction. IR spectra were recorded in KBr on Jasco FT-IR 5300 and major absorption was listed in cm⁻¹. ¹H-NMR and ¹³C-NMR spectra were taken at JEOL ECS-400 spectrometer (400MHz), and chemical shift were reported in ppm on the δ-scale from internal standard Me₄Si. MS spectra were measured with Agilent 6890N spectrometer using EI methods. TLC was carried out on aluminium plates coated with silica gel F₂₅₄ (E Merck) using UV lamp 254 nm to spot detection.

Synthesis of *N,N'*-Dibenzoyl-*N,N'*-Diethylureas

To *N,N'*-diethylurea in tetrahydrofuran (THF) and a few drops of pyridine, an equimolar of benzoyl chloride were added slowly at ice bath while stirring. Then the temperature was raised to 60 °C and the mixture were refluxed for 3 hours. Reflux was continued for 20 hours at room temperature. The mixture was concentrated by evaporating THF and the product was washed with water and saturated sodium bicarbonate respectively. The resulting solid was recrystallised from hot ethanol-water (1:1) to give *N,N'*-Dibenzoyl-*N,N'*-Diethylurea compounds **3a-d** (Fig.1).

Antitumor Activity

In vitro antitumor activity against MCF- 7 cancer cell lines was assayed by MTT method and expressed in IC₅₀, concentration of the compounds inducing a 50% inhibition of cell growth of treated cells compared to the growth of control cells. Hydroxyurea (HU) was used as the reference drug. Cancer cell lines were seeded at a density of 5x10³ cells/well in 96-well microplates. After 24 hours, exponentially growing cells were exposed to the test compounds in DMSO at final concentration ranging from 100 to 600 µg /mL. After 48 hours incubated in a 5 % CO₂ incubator at 37 °C, cell survival was determined by the addition of MTT solution (100 µL of 0.5 mg/ml MTT in PBS). Once formazan was formed, 100µL 10 % SDS in 0.1 N HCl was added and plates were incubated in the dark at 37 °C overnight. The absorbance was observed at 595 nm on ELISA-reader and survival ratio of living cells were expressed in percentages with respect to untreated cells. Each experiment was performed at least three times. The IC₅₀ value of test compounds were shown in Table 1.

Molecular Docking

Software and program

CS ChemBioDraw Ultra ver 11.0 (Cambridge Soft) was employed to built 3D structure of compounds and Molegro Virtual Docker (MVD) ver 5.0 (CLC Bio) was the docking program used in this research.

Docking Study

The structure of ERK2 (PDB ID = 1TV0, at 2,5 Å resolution) was obtained from the Protein Data Bank (www.pdb.org). Compound structures were built with ChemBioDraw Ultra 11.0 and their geometry optimization were performed using the MMFF94 method in the program and saved as Sybyl Mol2 format. In the molecular docking, the test compound were placed into binding site of 1TV0 (cavity-1) by align method to the reference ligand (FR180204). FR180204 is a selective inhibitor against ERK2 which complexed with this enzyme (13). The binding affinity between ligand and enzyme (docking score) was predicted using MolDock Score and post analysed as Rerank Score (RS). The highest-scoring pose (lowest energy) should represent the best-found binding mode. Evaluation of the interaction was based on the their RS which is the sum of ligand-protein interaction energy and internal ligand energy, including hydrogen bonds between ligands and protein. The validation of docking was carried out by redocking the FR180204 into cavity-1 of 1TV0.

A more negative binding affinity indicates stronger binding. The best docked structures have to follow these criteria : i) they have the lowest binding energy (highest-scoring pose); ii) geometrically, they must occupy the same cavity in the enzyme similar to FR180204. This can be observed visually by comparing the structure of docked molecule with crystal structure of FR180204 inside the binding site. The ligand-protein complexes of the top-scoring poses were used for further visual inspection (Fig. 2)

RESULTS AND DISCUSSION

Synthesis of *N,N'*-dibenzoyl-*N,N'*-diethylurea derivatives

Four *N,N'*-dibenzoyl-*N,N'*-diethylurea derivatives (**3a-d**) were synthesized from *N,N'*-diethylurea in one steps. All compounds are white solids and water insoluble substances. The structure of the synthesized compounds were identified by IR, ¹H-NMR, ¹³C-NMR, and MS spectroscopy as follows :

N,N'-carbonylbis(*N*-ethylbenzamide)=*N,N'*-dibenzoyl-*N,N'*-

diethylurea (**3a**). Yield 30% as white crystal, m.p. 147 °C. ¹H-NMR (CDCl₃, 400 MHz) : 1,1 (6H, t, *J*=7.2 Hz, CH₃); 3,2 (4H, m, CH₂); 7,3 (10H, m). NMR-¹³C (CDCl₃, 400 MHz) : 13,47 (CH₃); 42,99 (CH₂); 127,65 (=C aril); 128,67 (=C-C); 132,21 (=C-C); 136,03 (=C-C); 159,03 (C=O); 170,96 (C=O aril). IR (KBr), *v* maks (cm⁻¹) : 3087 (Csp₂-H), 2977 (C-H), 1717 (C=O ar), 1676 (-C=O(-N-)), 1580 (C=C), 858 (C-H aril). MS *m/z* EI : 324(M⁺), Calculated Mass C₁₉H₂₀N₂O₃ 324.15.

N,N'-carbonylbis(4-*tert*-butyl-*N*-ethylbenzamide)=*N,N'*-di(4-*tert*-butylbenzoyl)-*N,N'*-diethylurea (**3b**). Yield 20% as white crystal, m.p. 151 °C. ¹H-NMR (CDCl₃, 400 MHz) : 1,2 (6H, t, *J* = 6,8, CH₃); 1,3 (18H, s, -CH₃ *t*-butyl); 3,4 (4H, m, CH₂); 7,3 (4H, m, =CH aril); 7,5 (4H, m, =CH aril). NMR-¹³C (CDCl₃, 400 MHz) : 13,47 (CH₃); 31,25 (-CH₃ *t*-butyl); 35,26 (CH₂); 43,04 (-C- *t*-butyl); 125,55 (=C aril); 127,76 (=C aril); 130,16 (=C aril); 155,76 (=C aril); 159,03 (C=O); 171,33 (C=O aril). IR (KBr), *v* maks (cm⁻¹) : 3066 (Csp₂-H), 2968 (C-H), 1701 (C=O ar), 1683 (-C=O(-N-)), 1605 (C=C), 856 (C-H aril). MS *m/z* EI : 436 (M⁺), Calculated Mass C₂₇H₃₆N₂O₃ 436.27

N,N'-carbonylbis(*N*-ethyl-4-methoxybenzamide)=*N,N'*-di(4-methoxybenzoyl)-*N,N'*-diethylurea (**3c**). Yield 22% as white waxy solid, m.p. 79 °C. ¹H-NMR (CDCl₃, 400 MHz) : 1,1 (6H, t, *J* = 6,8, CH₃); 3,8 (4H, m, -CH₂); 4,3 (6H, s, -O-CH₃); 6,9 (4H, m, =CH aril); 8,04 (4H, m, =CH aril). NMR-¹³C (CDCl₃, 400 MHz) : 15,22 (CH₃); 35,43 (-CH₃ on ar-O-CH₃); 42,37 (CH₂); 114,22 (=C aril); 121,36 (=C aril); 128,32 (=C aril); 132,92 (=C aril); 162,38 (C=O); 164,65 (C=O aril). IR (KBr), *v* maks (cm⁻¹) : 3060 (Csp₂-H), 2979 (C-H), 1774 (C=O ar), 1711 (-C=O(-N-)), 1609 (C=C), 838 (C-H aril). MS *m/z* EI : 352 (M⁺), Calculated Mass C₂₁H₂₄N₂O₃ 352.18.

N,N'-carbonylbis(4-chloro-*N*-ethylbenzamide)=*N,N'*-di(4-chlorobenzoyl)-*N,N'*-diethylurea (**3d**). Yield 28% as white crystal, m.p. 141 °C. ¹H-NMR (CDCl₃, 400 MHz) : 1,1 (6H, t, *J* = 6,8, CH₃); 3,4 (4H, m, -CH₂); 7,3 (8H, m, =CH aril). NMR-¹³C (CDCl₃, 400 MHz) : 13,55 (CH₃); 43,25 (CH₂); 129,06 (=C aril); 134,06 (=C aril); 138,76 (=C aril); 158,37 (C=O); 170,18 (C=O aril). IR (KBr), *v* maks (cm⁻¹) : 3056 (Csp₂-H), 2974 (C-H), 1786, 1681 (-C=O amida), 1588 (C=C), 860 (C-H aril). MS *m/z* EI : 352 (M⁺), Calculated Mass C₂₁H₂₄N₂O₃ 352.18.

The *N,N'*-dibenzoyl-*N,N'*-diethylureas were produced by nucleophilic acylation between benzoyl chlorides and *N,N'*-diethylurea, where the nucleophile was *N,N'*-diethylurea. The structural change of (**2**) to *N,N'*-dibenzoyl-*N,N'*-diethylureas was characterized by the conversion of -NH- moiety of diethylurea to -N-C=O(Ar). As there are two symmetric -NH- moiety, the new compounds bear two symmetric substituted-benzoyl moieties, each attach on their N atom. It could be observed in ¹H-NMR spectra which didn't showed proton peak at -NH region, supported by IR spectra without N-H bands.

Antitumor Activity

Intending to find antitumor agent for breast cancer, we examined antitumor activity of the compounds *in vitro* on human breast carcinoma cell line (MCF-7). The results were listed in Table 1.

Table 1: IC₅₀ *in vitro* cytotoxicity of the tested compounds against human breast cancer cell (MCF-7) and their docking scores for ERK2 binding site

Compound	IC ₅₀ cytotoxicity (µM)	Rerank Score (RS)
3a	2,12	-69,157
3b	1,29	-90,857
3c	0,56	-81,665
3d	1,70	-77,189
HU	11,58	-38,297

Table 1 show that all tested compounds have IC₅₀ lower than anticancer drug hydroxyurea. Those indicated that all tested compounds had antitumor activity against MCF-7 cells higher than HU. It seems that benzoyl and ethyl group on the structure of urea may increase antitumor activity. HU that does not contain benzoyl group has low activity. Substituents on the benzene ring can also enhance the anticancer activity, depend on character of the

substituents. Compound without substituent on benzene ring (**3a**) show the lowest activity among the synthesized compounds. Compound with methyl substituents on the para-position (**3c**) exhibit the highest activity with IC_{50} of 0.56 μ M, about twenty-fold more active than HU with IC_{50} of 11.58 μ M. These results indicated that the *N,N'*-dibenzoyl-*N,N'*-diethylurea derivatives were potential as antitumor agents against breast carcinoma.

Docking Study

The capability of tested compounds to interact with target ERK2 was investigated by docking study, and the results were compared to HU (Table 2). Human breast cancer were known to overexpress in MAP kinase which is represented by ERK2 in this study, and HU could interacted with this enzyme [13]. Table 2 display better score (RS) for all *N,N'*-dibenzoyl-*N,N'*-diethylurea derivatives compared to the HU.




Fig. 2: Docked 3D conformation of best docked compound **3b** (Fig. 2A), reference drug HU (Fig. 2B), and most bioactive compound **3c** (Fig. 2C) showing hydrogen bonds with amino acid residues in ERK2 binding site (cavity-1). Pictures were created by Molegro version 5.5

The results indicate high predicted affinity of the new compounds to ERK2, with best values obtained for compound **3b**. The docking studies have shown more favorable interactions for the new dibenzoylurea derivatives with the target ERK2. Compound **3a** without substituent on benzene ring has the lowest affinity among the synthesized compound. It may explain that substituent on benzene ring contribute to their inhibitory activity. Interaction of molecules **3b**, **3c**, and HU with amino acid residues in binding site of ERK2 are shown in Figure 2.

Fig. 2A illustrate hydrogen bonding interaction between compound **3b** (best-docked molecule) and amino acid residue Lys 54, Fig. 2B show hydrogen bonding interactions of HU (reference drug) with Asp 106 and Met 108, and Fig. 2B display hydrogen bonds performed between compound **3c** (highest bioactivity) with Asn 154, Asp 167, Gln 105, and Lys 54. Hydrogen bonds performed by all synthesized compounds with amino acids in binding site of ERK2 were summarized in the Table 3.

Table 3: Hydrogen bonds performed by interaction between tested compounds and amino acids in binding site of ERK2

Amino acid	Compound				
	HU	3a	3b	3c	3d
Asn 154	-	-	-	+	-
Asp 106	+	-	-	-	-
Asp 167	-	-	-	+	-
Cys 166	-	+	-	-	+
Gln 105	-	++	-	+	+
Lys 54	-	+	+	+	-
Met 108	+	-	-	-	-

+ = hydrogen bond; ++ = two hydrogen bonds

- = no hydrogen bond

In Table 3 there can be seen variation of amino acids bound to each compound, but all of these amino acids perform hydrogen bonds with N-CO-N moiety of urea in the same binding site (cavity-1). It

appears from the presence of substituted-benzoyl group in synthesized compounds which doesn't exist in HU. These interaction denoted the importance of nitrogen atom for binding and the subsequent inhibitory capacity. Besides hydrogen bonding, there are steric interactions (van der Waals) performed by compounds with amino acid residues as shown in Fig. 3.

The *in silico* study indicated that different substituents on the aromatic ring could result in variations of hydrogen bonds and steric interactions. Such steric interactions supported the better score (RS) for compound **3b** compared to the HU (Table 2) although **3b** performed only one hydrogen bond. The methoxy substituent in compound **3c** performing additional hydrogen bonds with Asn 154 and Asp 167 (Fig. 3C) may contribute to its high bioactivity. The comparative docking study of the *N,N'*-dibenzoyl-*N,N'*-diethylurea derivatives with anticancer drug hydroxyurea supports the molecular design of this serie of compounds.




Fig. 3: 2D pictures showing hydrogen bonds (blue dashed-line) and steric interaction (red dashed-line) of best-docked compound **3b** (Fig. 3A), reference drug HU (Fig. 3B), and most potent compound **3c** (Fig. 3C) with amino acid residues in ERK2 binding site. Images were obtained from Molegro version 5.5.

CONCLUSION

The research concluded that four derivatives of *N,N'*-dibenzoyl-*N,N'*-diethylurea showed *in vitro* antitumor activity against human breast cancer cell line (MCF-7) higher than anticancer drug hydroxyurea. One of them (compound **3b**) displayed the highest activity among the tested compounds with IC_{50} 0.22 μ M, twenty-fold higher than hydroxyurea (IC_{50} = 11.58 μ M). *In silico* study could explained that their better inhibitory activity related to their higher affinity with ERK2 binding site. The presence of substituents on the aromatic ring increased the binding affinity and their bioactivity.

ACKNOWLEDGEMENT

We are thankful to our Professor, Mr. Siswandono, for guiding the use of docking program and to The Indonesian Higher Education Directorate for financial support (PUPT/Prime Research Grant for University in 2013).

REFERENCES

- Public Communication Center, General Secretary for Ministry of Health Republic of Indonesia. Statistik Penderita Kanker di Indonesia. www.puskom.depkes.go.id. Cited in March 12, 2013.
- Kar A. Medicinal Chemistry. 4th ed. New Delhi: New Age International Publishers Ltd; 2007.
- Lv PC, Zhou CF, Chen J, Liu PG, Wang KR, Mao WJ, et al. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors. Bioorganic & Medicinal Chemistry 2010; 18: 314-319.
- Chen F, Hancock CN, Macias AT, Joh J, Still K, Zhong S, et al. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorganic & Medicinal Chemistry Letters 2006; 16: 6281-6287.

5. Abouzid K, Shouman S. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. *Bioorganic & Medicinal Chemistry* 2008; 16: 7543-7551.
6. Saban N, Bujak M. Hydroxyurea Hydroxamic Acids and Derivatives as Antitumor Drugs. *Cancer Chemother Pharmacol* 2009; 64: 213-221.
7. Kurose A, Tanaka T, Huang X, Traganos F, Dai Wei, Darzynkiewicz Z. Effects of hydroxyurea and aphidicolin on phosphorylation of ataxia telangiectasia mutated on Ser 1981 and histone H2AX on Ser 139 in relation to cell cycle phase and induction of apoptosis. *Cytometry* 2006; Part A 69A: 212-221.
8. Campestre C, Agamennone M, Tortorella P, Prezioso S, Biasone A, Gavuzzo E, et al. *N*-Hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: Mode of binding in a complex with MMP-8. *Bioorganic & Medicinal Chemistry Letters* 2006; 16: 20-24.
9. Jin C, Liang YJ, He H, Fu L. Synthesis and antitumor activity of ureas containing pyrimidinyl group. *European Journal of Medicinal Chemistry* 2011; 46: 429-432.
10. Siswandono. The Synthesis of Benzoylurea and the Activity Test of Central Nervous System Depressant in *Mus Musculus*. *J Biosains Pascasarjana* 2003; 5, 1: 10-16.
11. Diyah NW, Siswandono, Hardjono S, Purwanto BT. Molecular modeling and QSAR of ring-substituted benzoylurea derivatives as potential antineoplastic agents. *Proceeding of Makassar Second International Symposium of Pharmaceutical Science* 2013: 46-48.
12. Otori M, Kinoshita T, Okuba M, Sato K, Yamazaki A, Arakawa H, et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. *Biochem Biophys Res Commun* 2005; 336: 357-363.
13. Wei F, Xie Y, He L, Tao L, Tang D. ERK1 and ERK2 kinases activate hydroxyurea-induced S-phase checkpoint in MCF7 cells by mediating ATR activation. *Cellular Signalling* 2011; 23: 259-268.